Analyst Eliana Merle from UBS maintained a Buy rating on Moderna and keeping the price target at $70.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Eliana Merle has given her Buy rating due to a combination of factors that suggest Moderna’s stock is poised for growth. One significant reason is the attractive valuation of the shares, which presents a compelling investment opportunity ahead of key pipeline readouts. Notably, the Phase 3 adjuvant melanoma data expected in 2026 could serve as a major catalyst for the stock, while additional data from Phase 2 trials for renal cell carcinoma and bladder cancer are anticipated to follow, potentially boosting investor confidence.
Furthermore, the upcoming clinical outcomes and PD-L1 expression analysis from the AIM-T program, expected to be presented at the European Society for Medical Oncology (ESMO) conference, have been highlighted by management as a crucial part of their pipeline strategy. Despite potential regulatory challenges, such as the discussions around COVID-19 vaccine access and safety, the overall outlook for Moderna remains positive, driven by these promising developments in their oncology pipeline.
Merle covers the Healthcare sector, focusing on stocks such as Ascendis Pharma, PTC Therapeutics, and Moderna. According to TipRanks, Merle has an average return of -3.4% and a 41.71% success rate on recommended stocks.